382 related articles for article (PubMed ID: 31088567)
1. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
[TBL] [Abstract][Full Text] [Related]
2. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
3. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
[TBL] [Abstract][Full Text] [Related]
4. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
[TBL] [Abstract][Full Text] [Related]
5. LINC00982-encoded protein PRDM16-DT regulates
Hu HF; Han L; Fu JY; He X; Tan JF; Chen QP; Han JR; He QY
Theranostics; 2024; 14(8):3317-3338. PubMed ID: 38855188
[TBL] [Abstract][Full Text] [Related]
6. S100A6 mediated epithelial-mesenchymal transition affects chemosensitivity of colorectal cancer to oxaliplatin.
Zhang C; Zeng M; Xu Y; Huang B; Shi P; Zhu X; Cao Y
Gene; 2024 Jul; 914():148406. PubMed ID: 38521111
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Lu WQ; Hu YY; Lin XP; Fan W
Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
[TBL] [Abstract][Full Text] [Related]
9. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
[TBL] [Abstract][Full Text] [Related]
10. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
11. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of EIF4A2 in non-small-cell lung cancer associates with poor prognosis.
Shaoyan X; Juanjuan Y; Yalan T; Ping H; Jianzhong L; Qinian W
Clin Lung Cancer; 2013 Nov; 14(6):658-65. PubMed ID: 23867391
[TBL] [Abstract][Full Text] [Related]
13. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
[TBL] [Abstract][Full Text] [Related]
14. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
Shi L; Xi J; Xu X; Peng B; Zhang B
Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
[TBL] [Abstract][Full Text] [Related]
15. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis.
Huang HL; Liu YM; Sung TY; Huang TC; Cheng YW; Liou JP; Pan SL
Theranostics; 2019; 9(22):6676-6689. PubMed ID: 31588243
[TBL] [Abstract][Full Text] [Related]
16. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
[TBL] [Abstract][Full Text] [Related]
17. PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
Igarashi H; Taniguchi H; Nosho K; Ishigami K; Koide H; Mitsuhashi K; Okita K; Takemasa I; Imai K; Nakase H
Clin Transl Oncol; 2020 Jul; 22(7):1126-1137. PubMed ID: 31741141
[TBL] [Abstract][Full Text] [Related]
18. DJ‑1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer.
Wang W; Wang H; Xiang L; Ni T; Jin F; Deng J; Zhang Y; Shintaro I; Zhou Y; Liu Y
Oncol Rep; 2020 Jul; 44(1):77-90. PubMed ID: 32627002
[TBL] [Abstract][Full Text] [Related]
19. RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer.
Wang H; Huang R; Guo W; Qin X; Yang Z; Yuan Z; Wei Y; Mo C; Zeng Z; Luo J; Cai J; Wang H
Clin Sci (Lond); 2020 Jul; 134(14):1973-1990. PubMed ID: 32677671
[TBL] [Abstract][Full Text] [Related]
20. Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer.
Zhang Q; Zhou Y; Feng X; Gao Y; Huang C; Yao X
Biomed Pharmacother; 2022 Sep; 153():113426. PubMed ID: 36017794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]